Bayer Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HLTHCARE, and what generic alternatives to BAYER HLTHCARE drugs are available?
BAYER HLTHCARE has fifty-six approved drugs.
There are thirty-eight US patents protecting BAYER HLTHCARE drugs.
There are seven hundred and seventy-six patent family members on BAYER HLTHCARE drugs in fifty-eight countries and one hundred and forty-seven supplementary protection certificates in twenty countries.
Summary for Bayer Hlthcare
International Patents: | 776 |
US Patents: | 38 |
Tradenames: | 57 |
Ingredients: | 37 |
NDAs: | 56 |
Drugs and US Patents for Bayer Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | ULTRAVIST 370 | iopromide | INJECTABLE;INJECTION | 020220-001 | May 10, 1995 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Hlthcare | UROVIST CYSTO | diatrizoate meglumine | SOLUTION;URETERAL | 087729-001 | Sep 23, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Hlthcare | ADEMPAS | riociguat | TABLET;ORAL | 204819-002 | Oct 8, 2013 | AB | RX | Yes | No | 11,203,593 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
Bayer Hlthcare | ASTEPRO ALLERGY | azelastine hydrochloride | SPRAY, METERED;NASAL | 213872-001 | Jun 17, 2021 | OTC | Yes | Yes | 9,919,050 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | DISCN | Yes | No | 8,613,950 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Hlthcare | YAZ | drospirenone; ethinyl estradiol | TABLET;ORAL | 021676-001 | Mar 16, 2006 | RE38253 | ⤷ Try a Trial |
Bayer Hlthcare | BEYAZ | drospirenone; ethinyl estradiol; levomefolate calcium | TABLET;ORAL | 022532-001 | Sep 24, 2010 | RE37564 | ⤷ Try a Trial |
Bayer Hlthcare | LEVITRA | vardenafil hydrochloride | TABLET;ORAL | 021400-003 | Aug 19, 2003 | 8,841,446 | ⤷ Try a Trial |
Bayer Hlthcare | ULTRAVIST (PHARMACY BULK) | iopromide | INJECTABLE;INJECTION | 021425-003 | Mar 12, 2004 | 4,364,921 | ⤷ Try a Trial |
Bayer Hlthcare | YASMIN | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 021098-001 | May 11, 2001 | 6,787,531 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 3 mg/0.03 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-09-28 |
➤ Subscribe | Transdermal System | 0.05 mg/day and 0.1 mg/day | ➤ Subscribe | 2005-09-12 |
➤ Subscribe | Tablets | 3 mg/0.02 mg | ➤ Subscribe | 2006-09-29 |
➤ Subscribe | Injection | 1.6 mg/mL | ➤ Subscribe | 2014-02-07 |
➤ Subscribe | Tablets | 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg | ➤ Subscribe | 2017-10-10 |
➤ Subscribe | Tablets | 0.25 mg/0.5 mg | ➤ Subscribe | 2015-01-08 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-11-13 |
➤ Subscribe | Tablets | 5 mg ad 10 mg | ➤ Subscribe | 2009-07-10 |
➤ Subscribe | Tablets | 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg | ➤ Subscribe | 2010-10-22 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2005-03-22 |
➤ Subscribe | Tablets | 40 mg | ➤ Subscribe | 2016-09-27 |
➤ Subscribe | Oral Suspension | 250 mg/5 mL and 500 mg/ 5 mL | ➤ Subscribe | 2009-10-16 |
➤ Subscribe | Tablets | 3 mg/0.03 mg | ➤ Subscribe | 2005-01-07 |
➤ Subscribe | Orally Disintegrating Tablets | 10 mg | ➤ Subscribe | 2011-12-22 |
➤ Subscribe | Tablets | 0.5 mg/1 mg | ➤ Subscribe | 2007-12-26 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2011-11-21 |
➤ Subscribe | Tablets | 20 mg | ➤ Subscribe | 2009-03-05 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2009-09-04 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2014-02-28 |
International Patents for Bayer Hlthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2015010725 | ⤷ Try a Trial |
European Patent Office | 1858490 | ⤷ Try a Trial |
South Africa | 200702510 | ⤷ Try a Trial |
South Africa | 200709012 | ⤷ Try a Trial |
South Africa | 200408925 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Hlthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0398460 | 12/2004 | Austria | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211 |
1453521 | C201630040 | Spain | ⤷ Try a Trial | PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211 |
3106463 | 2090009-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923 |
1663978 | SPC/GB13/076 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: REGORAFENIB AND ITS SALTS; REGISTERED: UK EU/1/13/858/001 20130829; UK EU/1/13/858/002 20130829 |
3106463 | 20C1012 | France | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SULFATE DE LAROTRECTINIB TEL QUE L'HYDROGENOSULFATE DE LAROTRECTINIB; NAT. REGISTRATION NO/DATE: EU/1/19/1385 20190923; FIRST REGISTRATION: DE - EU/1/19/1385 20190923 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.